{
  "abstract": "Background Sorafenib is a multi-kinase inhibitor targeting several intracellular and cell surface kinases. It is indicated as a monotherapy for the treatment of unresectable hepatocellular carcinoma. Regorafenib has been approved as a second-line therapy for patients who have progressed on sorafenib treatment.Aim To assess the efficacy and safety of regorafenib in Egyptian patients with HCC who have progressed on sorafenib treatment. Assessment of drug adverse effects and tumor response by modified Response Evaluation Criteria in Solid Tumors (mRECIST).Methods A total of 248 patients with advanced HCC were included in this study (from January 2022 to January 2025), who received sorafenib treatment according to the BCLC staging system.Fifty-five patients were shifted to regorafenib after failure to respond to initial sorafenib therapy. Data collected included patient demographics, performance status, duration of previous line of treatment, number of treatment cycles, side effects, best-tolerated dose, laboratory, and radiological results. The overall survival (OS) and progression-free survival (PFS) were assessed. Patients were prospectively registered and initially received ≤160 mg oral regorafenib daily for weeks 1–3 of each 4-week cycle.Results Out of 248 patients who initially received sorafenib, 55 patients were shifted to regorafenib as a second-line therapy after progression on sorafenib. Of those, 19 patients (34.5%) and 36 patients (65.5%) were classified as BCLC stages B and C, respectively. Twenty-two patients (40%) had disease progression with a median disease-free progression period of 10 months [95% confidence interval (CI): 9.584 - 10.416], 36 patients (65.5%) were deceased and eventually, only one patient (1.8%) achieved a complete response. The median survival time was 14 months (95% CI, 11.718 - 16.282). The most common adverse events were liver decompensation (47.27 %), fatigue (36.8 %), abdominal pain and diarrhea (19.3%), and alopecia in one case (0.02%). The most common grade 3–4 adverse events were hypoalbuminemia (9.7%), oral ulcers (5.5%) and anemia (2.8%).Conclusions Regorafenib was found to be safe and clinically effective in Egyptian patients with advanced HCC who progressed on first-line sorafenib.",
  "authors": [
    {
      "affiliations": [
        "Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Egypt"
      ],
      "name": "Mohamed Ahmed Samy Kohla"
    },
    {
      "affiliations": [
        "Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Egypt"
      ],
      "name": "Eman Rewisha"
    },
    {
      "affiliations": [
        "Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Egypt"
      ],
      "name": "Eman Elkhateeb"
    },
    {
      "affiliations": [
        "Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Egypt"
      ],
      "name": "Moustafa Elhelbawy"
    },
    {
      "affiliations": [
        "Department of Radiology, National Liver Institute, Menoufia University, Egypt"
      ],
      "name": "Mohamed Houseni"
    },
    {
      "affiliations": [
        "Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Egypt"
      ],
      "name": "Hossam El-Din Taha"
    }
  ],
  "title": "IDDF2026-ABS-0111 Efficacy and safety of sorafenib-regorafenib sequential therapy for Egyptian patients with an advanced stage HCC",
  "uid": "a0aded83-f1cc-5faa-924d-ba0b1af0e383"
}